Ingen Technologies achieves ISO 13485 Certification

Ingen Technologies, Inc. (IGNT), which provides innovative oxygen cannulas to home care providers similar to Lincare Holdings (LNCR) and Cardinal Health, Inc. (CAH), could see tremendous growth ahead as COPD continues to be a problem both domestically and abroad.

Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading manufacturer of respiratory medical devices, recently announced today that the company is officially ISO 13485 Certified.

The ISO certificate is available to view at http://media.globenewswire.com/cache/6574/file/8005.pdf

In the U.S. alone, COPD is the third leading cause of death with annual costs estimated at $40 billion. Meanwhile, the disease is projected to become the third biggest killer in the entire developed world by 2020. In fact, COPD is the only major disease with an increasing death rate, which is rising at a rate of about 16%, according to the Center for Disease Control (CDC). Perhaps the most common treatment for those with COPD is the use of supplementary oxygen, which helps make it easier for patients to breathe and receive the oxygen level they need. Every single one of these patients requires an oxygen cannula in order to receive the oxygen from the delivery source.

The market for oxygen cannulas is estimated to be around $400 to $500 million in size. Most of the market consists of cannulas that are manufactured overseas and imported at a low cost, since the product is widely believed to be commoditized. However, Ingen Technologies is preparing to change the industry with its "smart" cannulas.

Ingen's Smart Nasal Cannula® includes its disposable in-line Oxyview® flow meter that provides assurance and confirms the oxygen flow rate and equipment function for the patient. In a market where most patients operate out of their home, false alarms can be very costly for home care providers like Lincare Holdings (LNCR) and Cardinal Health (CAH).

"Ingen Technologies is rapidly executing on its business plan and has achieved ISO certification to sell internationally. KGMA is now increasing potential government orders under its pending GSA certification to sell to the U.S. government, and by lining up distributors to help increase its initial sales within the VA Hospitals and Department of Defense. Meanwhile, Ingen's growing patent portfolio not only protects its intellectual property, but also adds value to the organization. As more customers discover the benefits of this new smart nasal cannula with Oxyview technology, investors may see sales and profits quickly ramp up going forward." Stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.